The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Conclusions: This real-world retrospective analysis found that the rate of VTE events among newly diagnosed cancer patients who were initiated on cancer therapy significantly increased with VTE risk level based on the KRS. Over 25% of patients in the observed cohort have KRS≥2 and are 3 times more likely to develop VTE from the time of cancer diagnosis. These findings further validate the KRS in contemporary oncology patients and support ongoing studies of thromboprophylaxis in patients with a score of 2 or higher.DisclosuresKhorana: Sanofi: Consultancy; Bayer: Consultancy; Pfizer: Consultancy; Janssen: Consultancy. Kuderer: Celldex: Consultancy; Mylan: Consultancy, Other: Travel, Accommodations, Expenses; Coherus Biosciences: Consultancy, Other: Travel, Accommodations, Expenses; Halozyme: Consultancy; Myriad Genetics: Consultancy; Pfizer: Consultancy; Janssen Scientific Affairs, LLC: Consultancy, Other: Travel, Accommodations, Expenses. Milentijevic: Janssen Scientific Affairs, LLC: Employment, Equity Ownership. Germain: Janssen Scientific Affairs, LLC: Research Funding. Laliberté: Janssen Scientific Affairs, LLC: Research Funding. Le: Janssen Scientific Affairs, LLC: Research Funding. Lefebvre: Janssen Scientific Affairs, LLC: Research Funding. Lyman: Generex Biotechnology: Membership on an entity's Board of Directors or advisory committees; Halozyme; G1 Therapeutics; Coherus Biosciences: Consultancy; Amgen: Other: Research support.

Source: Blood - November 21, 2018 Category: Hematology Authors: Khorana, A. A., Kuderer, N. M., McCrae, K. R., Milentijevic, D., Germain, G., Laliberte, F., Le, N., Lefebvre, P., Lyman, G. H., Streiff, M. B. Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research